Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.61 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.49 |
| ▸ | TP53 | P04637 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795111 | 0.90 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL6797503 | 0.89 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL6802244 | 0.86 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL6796438 | 0.81 | PLK1 (0.48) | NPC1TP53LMNATSHRHPGD | |
| SCHEMBL6797644 | 0.81 | RXFP1 (0.42) | NPC1RAB9ASMN1; SMN2TSHRHPGD | |
| SCHEMBL6796357 | 0.79 | RXFP1 (0.42) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL6796389 | 0.75 | PDE1A (0.40) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL6795642 | 0.75 | L3MBTL1 (0.40) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL7045495 | 0.74 | L3MBTL1 (0.39) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL6791736 | 0.74 | TP53 (0.60) | NPC1RAB9ASMN1; SMN2TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747035-B2 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | WARNER-LAMBERT LLC | 2004-06-08 | — | — | US | claimed |
| US-20030069260-A1 | 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | GUADILLIERE BERNARD (FR) | 2003-04-10 | — | — | US | claimed |
| EP-1285922-A1 | 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | WARNER-LAMBERT COMPANY (US) | 2003-02-26 | — | — | EP | claimed |
| US-6747035-B2 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | WARNER-LAMBERT LLC | 2004-06-08 | — | — | US | disclosed |
| EP-1419159-A1 | 1-ALKYL 0R 1-CYCLOALKYLTRIAZOLO 4,3-A]QUINAZOLIN-5-ONES AS PHOSPHODIESTERASE INHIBITORS | Warner-Lambert Company LLC (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030069260-A1 | 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | GUADILLIERE BERNARD (FR) | 2003-04-10 | — | — | US | disclosed |
| WO-2003016314-A1 | 1-ALKYL 0R 1-CYCLOALKYLTRIAZOLO[4,3-A]QUINAZOLIN-5-ONES AS PHOSPHODIESTERASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1285922-A1 | 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | WARNER-LAMBERT COMPANY (US) | 2003-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069260-A1 | 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | PDE3A, PDE4A, PDE5A | NPC1 2456/4885RAB9A 2106/4885SMN1; SMN2 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.